Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital Department of Defense |
---|---|
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00165204 |
Women undergoing surgical menopause often experience marked menopausal side effects but are reluctant to use estrogen or other female hormones to ease the transition to menopause because of worries that the hormones may increase breast cancer risks. This study will evaluate tibolone in women experiencing surgical menopause to assess its effects on bone health, menopause symptoms and breast density.
Condition | Intervention | Phase |
---|---|---|
Menopause Postmenopausal Bone Loss Breast Cancer |
Drug: Tibolone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study |
Official Title: | A Randomized Study of the Effects of Tibolone on Bone Density, Menopause Symptoms and Breast Density in High Risk Women After Prophylactic Oophorectomy |
Estimated Enrollment: | 50 |
Study Start Date: | April 2004 |
Study Completion Date: | March 2006 |
Primary Completion Date: | March 2006 (Final data collection date for primary outcome measure) |
Women interested in participating in this study will be allowed to use hormones to manage symptoms for up to 3 months before beginning the study. Those choosing not to take hormones may enroll in the study immediately.
All women will have a baseline mammogram, breast examination, and bone study density performed, along with blood and urine analysis for measurement of bone markers. They will also be asked to take a questionnaire.
Patients will take either tibolone or placebo once daily for 1 year. Neither the patient or the physician will be aware of which treatment a woman is taking during the study.
Patients will return at 6 and 12 months to have a physical examination, blood work, urine collection and bone studies. At one year, a repeat mammogram will be performed. There are also some questionnaires asking about menopause symptoms that will be performed at intervals during the study.
It is also recommended that patients take calcium and vitamin D throughout the study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Dana-Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Judy Garber, MD, MPH | Dana-Farber Cancer Institute |
Study ID Numbers: | 03-363 |
Study First Received: | September 9, 2005 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00165204 History of Changes |
Health Authority: | United States: Institutional Review Board |
Tibolone High risk women Oophorectomy Breast Density Bone Density |
Estrogens Antineoplastic Agents, Hormonal Skin Diseases Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Breast Neoplasms Osteoporosis Bone Diseases, Metabolic Cardiovascular Agents Antihypertensive Agents Bone Diseases |
Hormones Estrogen Receptor Modulators Anabolic Agents Tibolone Androgen Antagonists Musculoskeletal Diseases Osteoporosis, Postmenopausal Breast Diseases Menopause Androgens |
Antineoplastic Agents, Hormonal Skin Diseases Antineoplastic Agents Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Breast Neoplasms Osteoporosis Bone Diseases, Metabolic Cardiovascular Agents Antihypertensive Agents Hormones |
Bone Diseases Pharmacologic Actions Estrogen Receptor Modulators Anabolic Agents Neoplasms Tibolone Androgen Antagonists Neoplasms by Site Musculoskeletal Diseases Therapeutic Uses Osteoporosis, Postmenopausal Breast Diseases |